A Look to the Environment and the Impact on OPEX

Thomas Friedli () and Daniel Bellm ()
Additional contact information
Thomas Friedli: University of St.Gallen
Daniel Bellm: University of St.Gallen

Chapter Chapter 6 in Leading Pharmaceutical Operational Excellence, 2013, pp 77-102 from Springer

Abstract: Abstract With a glimpse to global stock markets, the pharmaceutical industry has performed poorly compared to other industries over the last 10 years. Positive influencing factors like the strong growth in emerging markets (see Fig. 6.1), the aging population and influenza pandemics seem to be counterbalanced by other factors like increasing competition, the global financial and debt crisis, the patent cliff, an increasing complexity and a declining R&D productivity.

Keywords: Pharmaceutical Industry; Pharmaceutical Company; Generic Substitute; Product Portfolio; Branded Drug (search for similar items in EconPapers)
Date: 2013
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:sprchp:978-3-642-35161-7_6

Ordering information: This item can be ordered from
http://www.springer.com/9783642351617

DOI: 10.1007/978-3-642-35161-7_6

Access Statistics for this chapter

More chapters in Springer Books from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().